Finasteride Tablet, Film Coated
Product Images NDC 65862-149

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 65862-149). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

The text appears to be a table showing mean change from baseline + 1 SE, along with a figure indicating symptom score in 2 long term efficacy and safety studies. The table compares the results of a placebo treatment versus a treatment of Finasteride, with baseline and yearly scores over four years. Therefore, it can be inferred that the context of this text is a medical study, likely exploring the effectiveness and safety of Finasteride as a treatment for a particular medical condition.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

This is a graph named "Percent of Patients Having Surgery for BPH, Including TURP" with observation time in months on the X-axis and percentage of patients on the Y-axis showing the result of a trial where Finasteride was given to patients with BPH and the number of surgeries performed. The graph shows that the Finasteride group had a lower percentage of patients needing surgery for BPH than the placebo group at 15% and 0%, respectively, after 48 months of observation time. The graph also shows additional information in tabular form for the number of events, cumulative events, and number at risk per year for both the placebo and Finasteride groups.*

FDA Label Image

Figure 4 Prostate Volume In A Long-term Efficacy And Safety Study (Finasteride Fig3)

The text is a figure that shows the percentage of patients developing acute urinary retention over time in a clinical trial that compared finasteride to a placebo. The data is presented graphically and includes the number of events and patients at risk at different time points.*

FDA Label Image

Figure 5 Cumulative Incidence Of A 4-point Rise In Aua Symptom Score By Treatment Group (Finasteride Fig4)

This is a visual representation of the mean percent change from baseline in prostate volume in a long-term study evaluating the efficacy and safety of finasteride compared to placebo over the course of 4 years. The table shows the number of participants for each group and their corresponding prostate volume measurements at baseline and over the duration of the study.*

FDA Label Image

Finasteride-fig5 (Finasteride Fig5)

The image shows a graph with the cumulative incidence of a 4-point rise in AUA Symptom Score by treatment group over time (years from randomization). The vertical axis represents the percent with the event, ranging from 0 to 25%. The horizontal axis shows the years from randomization from 0 to approximately 55 years.*

FDA Label Image

Finasteride Fig6

FDA Label Image

Chemical Structure (Finasteride Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.